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1 
INTRODUCTION 
 
Jaundice is probably the most common newborn infant problem dealt with on a daily 
basis by the family practitioner and paediatrician.  Jaundice occurs when the liver 
cannot clear a sufficient amount of bilirubin from the plasma.  When the problem is 
excessive bilirubin formation or limited uptake or conjugation, unconjugated (i.e., 
indirect reacting) bilirubin appears in the blood and indirect hyperbilirubinemia is the 
predominant form of jaundice found in the newborn infant.  In the vast majority of 
newborns, hyperbilirubinemia is transient and benign but, in rare cases, the serum 
bilirubin rises to a level that is toxic to the central nervous system.  Understanding the 
pathogenesis and epidemiology of neonatal hyperbilirubinemia; recognizing, the 
problems involved in appropriate surveillance and monitoring of the jaundiced infant and 
the factors contributing to bilirubin encephalopathy; and implementing treatment of the 
jaundiced neonate in a timely fashion, are issues that have engaged clinicians and 
researchers for some 6 decades.  This work will summarize my contributions to the field 
of neonatal hyperbilirubinemia and it includes papers published between 1971 and 
2007.  The description of this work will not follow its chronological sequence, but will be 
divided into the categories of diagnosis, epidemiology, pathogenesis, management, 
treatment, and bilirubin encephalopathy. 
 
DIAGNOSIS – STUDIES USING TRANSCUTANEOUS BILIRUBIN MEASUREMENTS 
When the bilirubin concentration in the serum increases, bilirubin is deposited in the 
skin and subcutaneous tissues producing the (yellow) physical sign of jaundice or 
icterus.  There is a well established relationship between the total serum bilirubin (TSB) 
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concentration and the intensity of jaundice, and the assessment of skin color in 
quantifying the level of bilirubin in the plasma has been utilized as a clinical sign since 
the early part of the 20th Century.  As it is neither possible, nor desirable to measure the 
serum bilirubin daily in every infant for the first week after birth, clinicians have used the 
clinical sign of jaundice as the trigger for deciding when to measure the TSB 
concentration. 
 
Although there is a clear and semi-quantitative relationship between the yellowness of 
the skin and the TSB, the variations in colour perception by the human eye, differences 
in neonatal skin pigmentation, and variations in both the intensity and colour of the 
available light affect our ability to estimate TSB by assessing the degree of jaundice.  
Several studies have shown that practitioners provide wide ranges of estimates of TSB 
concentrations based on their clinical observations. 
 
Recognition of the inaccuracy of the clinical estimation of TSB has led to the 
development of non-invasive instruments that can provide an objective measurement of 
skin colour.  The first such electronic device made available for commercial distribution, 
the Jaundice Meter, was produced by the Minolta Camera Company and consisted of a 
hand-held instrument that measured the yellow color intensity of the skin and 
subcutaneous tissues.  When a photoprobe is pressed against the infant’s skin to a 
pressure of approximately 200g, a xenon tube produces a strobe light that travels 
through a fiberoptic filament to the photoprobe.  The bright light penetrates the blanched 
skin and transilluminates the subcutaneous tissue.  The scattered light returns through a 
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second fiberoptic filament and is carried to the spectrophotometric module.  Inside the 
module, the light is divided by a dichroic mirror into two spectra, one of which passes 
through a blue filter (maximum absorption, 460nm) and the other through a green filter 
(maximum absorption, 550nm).  Absorption at these spectra corrects for hemoglobin 
and the intensity of the yellow colour is measured as the difference between the optical 
densities of blue and green processed electronically to provide a digital meter reading.  
This instrument provided a read out of a “transcutaneous bilirubin index.”  Based on 
correlative data from the particular hospital laboratory and patient population, this index 
could then be converted to a serum bilirubin level. 
 
Transcutaneous Bilirubin Measurements in Full-Term Infants 
To document the utility and accuracy of this instrument, in 1982 I performed 292 
transcutaneous bilirubin (TcB) measurements in 157 full term infants.1  Having 
established that TcB measurements correlated well with TSB determinations (r=.93, 
p<.001), I evaluated the ability of the Jaundice Meter to identify infants whose TSB 
concentrations exceeded 12.9 mg/dL (221 µmol/L).  Using a TcB index value of 24, the 
TcB measurement had a sensitivity of 100%, a specificity of 97%, and a negative 
predictive value of 100% for identifying a TSB level of 12.9 mg/dL (221 µmol/L).  Thus a 
TcB index < 24 correctly predicted the absence of TSB ≥ 12.9 mg/dL (221 µmol/L) in all 
cases.   
 
I also compared the correlation between TcB and TSB when measured at the forehead 
or sternum and found that both of these measurements were equally accurate.  I 
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concluded that, if used as a screening device, the TcB instrument would, with an 
acceptable degree of accuracy, identify those infants who required a serum bilirubin 
determination.   
 
Interinstrument Variability 
Because interinstrument variability of the Jaundice Meter had not been well studied, we 
evaluated the response of 4 TcB meters in a population of 72 newborn infants.2In this 
study, sequential readings were taken in random order from the forehead of each infant 
using 4 separate TcB meters.  The order was randomized using a 4x4 Latin square 
design.  Each instrument was calibrated by the manufacturer and the calibration was 
checked against the color standard provided.  We used the average of the readings 
from the 4 instruments as the closest practical approximation to a theoretical “true mean 
value” and calculated the standard error of the estimate to provide the confidence limits 
about this mean.  We found that 2 of the meters provided measurements that were 
consistently higher than the other 2 meters and that the differences were systematic 
and not random.  Our calculations showed that, in 95% of cases, the measurement 
would provide a TcB index that was within ± 4.24 transcutaneous bilirubin units of the 
true value and this degree of error would represent approximately ± 2.8 mg/dL (47.9 
µmol/L) of serum bilirubin.  We therefore recommended that individual hospital 
laboratories should construct their own regression lines for each instrument using the 
serum bilirubin measurement as the independent variable and the transcutaneous 
bilirubin index as the dependent variable. 
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Cost Effectiveness 
A question that must be asked about every screening test is: is this test cost effective?  
We therefore wanted to know whether or not the routine use of the Jaundice Meter as a 
screening tool in the newborn nursery would reduce both the need for serum bilirubin 
measurements and costs.  In this study 3 we first established the relationship between 
TSB levels and the TcB index in 356 newborns of ≥ 36 weeks gestation.  We then 
introduced the routine clinical use of the jaundice meter and documented the impact of 
routine TcB measurements on the number of TSB measurements obtained over a 2-
year period.  In addition, we calculated the total direct costs for performing serum 
bilirubin measurements in the clinical laboratory and the TcB index in the nursery.  We 
showed that the use of the jaundice meter produced a 36% reduction in the number of 
TSB measurements sent to the laboratory and generated cost savings of some 
$1600/year.   
 
Newer Jaundice Meters 
The initial models of the Minolta jaundice meters had some significant disadvantages.  
They did not provide a read-out of the serum bilirubin concentration; a TcB index was 
displayed and TSB values were derived from the TcB index on the basis of data 
obtained in individual hospital laboratories.  TcB readings were also significantly 
affected by gestation and skin pigmentation.  As a result, these instruments achieved 
limited acceptance in hospitals in the United States, although they were widely used in 
Japan.  Subsequently Minolta developed the JM-102 and, its latest model the JM-103 
which has overcome some of the disadvantages of the earlier models.  The JM-103 TcB 
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instrument uses two wavelengths and a dual optical path system.  The principal of 
operation includes the formation of two beams, one of which reaches only the shallow 
areas of the subcutaneous tissue, while the other penetrates the deeper layers.  The 
differences between the optical densities are detected by blue and green photocells.  
Measurement of bilirubin accumulated primarily in the deeper subcutaneous tissue 
should decrease the influence of other pigments in the skin, such as melanin and 
hemoglobin.  These innovative technologies should reduce the effect of race, age, 
gestation and birth weigh on TcB measurements.  The JM-103 also contains an 
algorithm that converts the intensity of the yellow colour reading directly to a serum 
bilirubin concentration, (rather than an index that needs to be converted to a TSB value) 
and displays this as a digital readout.   
 
In 2004 we published the first large study evaluating the new Minolta JM-103.4  In this 
study we compared TSB measurements with TcB measurements in 849 newborns ≥ 35 
weeks of gestation.  This was a mixed population consisting of 59% White, 30% Black, 
5% East Asian, 4% Middle Eastern and 3% Indian/Pakistani and Hispanic patients.  We 
found a close correlation between TSB and TcB values in all of the population groups 
White (n=503, r=0.949); Black (n=253, r=.822); East Asian, Indian/Pakistani and 
Hispanic (n=93, r=.926).  In the black population, the correlation was less close than in 
other groups but, because the tendency in blacks is for the TcB measurement to over 
estimate TSB levels, dangerous clinical errors are unlikely to occur.  The measurement 
technique is rapid and simple and it is easy to perform repeated measurements over 
time, thus reducing the likelihood of error.  TcB measurements with the JM-103 jaundice 
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meter should obviate the need for most serum bilirubin measurements in newborn 
infants ≥ 35 weeks of gestation.  We now use this instrument in our newborn nursery as 
a routine screening device and the nurses obtain a daily TcB measurement on every 
infant during the midnight shift.  Prior to its use, about 30% of infants in our nurseries 
had at least one TSB level measured.  Using the JM-103 as a screening device, only 
9% of infants currently have at least 1 TSB measured (unpublished data). 
 
The Natural History of Bilirubinemia 
There are currently no good published data on the natural history of bilirubinemia in the 
newborn.  There is a nomogram that is widely used in nurseries throughout the United 
States and other countries to help identify infants who are likely or unlikely to 
subsequently develop hyperbilirubinemia.  Unfortunately, because of significant biases 
in the population sampled, this nomogram does not represent the natural history of 
neonatal jaundice.  To address this issue we performed 9,397 TcB measurements on 
3,984 healthy newborn infants (gestational age ≥ 35 weeks) between 6-96 hours of 
age.5 All these measurements were performed with the JM-103 jaundice meter at 6-
hour intervals.  With this study we were able to achieve two objectives.  The first was to 
establish a nomogram (the 5th, 25th, 50th, 75th and 95th percentiles) of the natural history 
of bilirubinemia in the first 96 hours of life, and the second was to establish the rate of 
rise of bilirubin levels over the first 96 hours.  From these data we concluded that infants 
whose bilirubin levels were increasing more rapidly than 0.22 mg/dL (3.8 µmol/L) per 
hour in the first 24 hours, 0.15mg/dL (2.6 µmol/L) between 24-48 hours, and 0.06 
mg/dL/hr (1µmol/L) after 24 hours need closer observation and evaluation as these 
 8 
rates of rise suggest the presence of hemolysis.  The data and the nomogram that we 
developed are useful in detecting aberrant trends and identifying infants who need 
additional evaluation as well as in planning for appropriate follow up for jaundiced 
newborns, particularly those in whom TcB measurements were obtained prior to 
discharge. 
 
Predicting Hyperbilirubinemia 
Most recently we have evaluated the utility of using predischarge TcB measurements as 
a predictor of subsequent hyperbilirubinemia.6  In this study we were able to show that a 
predischarge TcB measurement above the 95th percentile indicated that the risk of that 
infant subsequently developing a TSB of 17 mg/dL (291 µmol/L) was 47.9 times greater 
than an infant whose predischarge TSB was below the 50th percentile.  Of 4,854 infants 
with predischarge TcB levels below the 50th percentile, none developed a TSB > 20 
mg/dL (342 µmol/L).  Thus, a predischarge TcB is a valuable tool in helping to predict 
which infants are likely or unlikely to develop significant hyperbilirubinemia following 
discharge. 
 
Outpatient Use of TcB Measurements 
Almost all of the studies of TcB measurements to date have been performed in hospital 
settings and it was important to know whether this instrument would be valuable when 
used in an outpatient setting.  To this end we have obtained TcB measurements in 4 
private paediatric practices as well as in the paediatric outpatient clinics of the William 
Beaumont Hospital.7  In a population of 116 infants we found an excellent correlation 
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between TcB and TSB (r=.846, p=0.0).  We were also able to show that the age of the 
infant (up to 12.6 days) had no effect on the difference between TSB and TcB.  These 
data demonstrate that TcB measurements can be used with confidence in paediatric 
offices to identify those infants who do or do not require a TSB measurement. 
 
Historical Perspectives 
Finally I authored a paper reviewing the history and current use of transcutaneous 
measurements,8 in which I provide practical advice for the use of this measurement in 
paediatric practice. 
 
EPIDEMIOLOGY – STUDIES OF BREASTFEEDING AND OTHER EPIDEMIOLOGIC 
FACTORS IN NEWBORN JAUNDICE 
 
Breastfeeding, Weight Loss and Jaundice 
In a series of publications9-14 I have identified, amongst other things, the major 
epidemiologic risk factors for the development of hyperbilirubinemia.  In the first study 
we investigated the weight loss experienced by 40 breastfed infants and its association 
with jaundice and fever.9  There is surprisingly little published data on the normal weight 
loss to be expected for fully breastfed infants, particularly when these infants are divided 
into different weight group categories.  In addition, it was unclear whether the fever that 
occurs occasionally in breastfed infants is related to under nutrition or dehydration.  In 
this study we reviewed the charts of 100 infants from the well baby nursery, 25 infants in 
each of 4 weight groups (birth weight 2501-3000g, 3001-3500g, 3501-4000g, and > 
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4000g).  These infants were selected only if they had been delivered vaginally and had 
been fully breastfed and had received no supplementation with water or formula.  All 
infants were nursed by their mothers soon after birth and were breastfed subsequently 
on demand.  In this study we found no relationship between serum bilirubin 
concentrations and weight loss and we also found that those infants who became febrile 
did not have excessive weight loss.  The average weight loss for all infants was 5.8 ± 
3.2% and we concluded that intervention was appropriate for infants whose weight loss 
exceeded 12%, not 5-7% as had been suggested. 
 
The Role of Breastfeeding and Other Causes in Neonatal Jaundice 
The association between breastfeeding and hyperbilirubinemia has been debated and 
extensively investigated over the last 30 years.  We performed TSB determinations on 
264 term infants who were consecutively delivered via the vaginal route.10  On the third 
hospital day, the mean (± SD) TSB level was 6.9 ± 3.6 mg/dL (118 ± 62 µmol/L) in the 
breastfed infants and 6.5 ± 3.2 mg/dL (111 ± 55 µmol/L) in formula fed infants.  These 
TSB levels were determined in every case on the third hospital day.  We concluded that 
breastfeeding did not affect the TSB level in the first 3 days although, because of the 
small sample size, there remained the possibility of a type II error.  41 infants had TSB 
concentrations > 12 mg/dL (246 µmol/L) on the third day and additional investigations 
(ABO and Rh blood typing, direct antibody test, reticulocyte counts and red blood cell 
morphology) were performed on these infants in attempt to identify the cause for the 
hyperbilirubinemia.  No cause could be found for the hyperbilirubinemia in 49% of these 
infants.  
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Normal Serum Bilirubin Levels and the Effect of Breastfeeding 
Recognizing that the population that we had previously analyzed was quite small, we 
studied a substantially larger population to document normal serum bilirubin levels in 
the newborn and the effect of breastfeeding.11  In this study we measured TSB 
concentrations in 2,416 consecutive infants admitted to the well baby nursery and found 
that the maximum TSB exceeded 12.9 mg/dL (221 µmol/L) in 147 infants (6.1%).  We 
compared these infants with 147 randomly selected control infants with maximum TSB 
levels ≤ 12.9 mg/dL (221 µmol/L).  In 66 infants (44.9%) we identified an apparent 
cause for the jaundice but in 81 (55%) no cause was found.  Of those infants for whom 
no cause for hyperbilirubinemia was found, 82.7% were breastfed versus 46.9% in the 
control group (p < .0001).  Breastfeeding was therefore significantly associated with 
hyperbilirubinemia even in the first 3 days of life.  The 95th percentile for formula fed 
infants was a TSB level of 11.4 mg/dL (195 µmol/L) versus 14.5 mg/dL (248 µmol/L) for 
the breastfed population.  Of the formula-fed infants 2.24% had TSB levels > 12.9 
mg/dL (221 µmol/L) versus 8.97% of breastfed infants (p < .000001).  We therefore 
identified a strong association between breastfeeding and jaundice in the healthy 
newborn infant.  We concluded that investigations for the cause of hyperbilirubinemia in 
healthy breastfed infants were not indicated unless a serum bilirubin level exceeded 
approximately 15 mg/dL (385 µmol/L), whereas in the formula fed infants such 
investigations were indicated if the TSB exceeded approximately 12 mg/dL (205 
µmol/L). 
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Quantifying the Risk Factors for Jaundice 
The data from this study population of 2,416 infants permitted us to do additional 
analysis.12  Using stepwise logistic regression we were able to provide a quantifiable 
risk score for the risk of developing a TSB > 12.9 mg/dL (221 µmol/L) depending on the 
presence or absence of certain risk factors.  Thus a 38 week gestation, male infant of a 
diabetic mother whose labour was induced with oxytocin and who was breastfed and 
had a 10% weight loss, had an 84% chance of developing a TSB > 12.9 mg/dL (221 
µmol/L).  On the other hand an infant born at 39 weeks gestation with none of the above 
listed risk factors and only a 5% weight loss had only a 1.4% risk of developing a TSB 
level of 12.9 mg/dL (221 µmol/L).   
 
We were therefore able to show that infants that have a number of risk factors can be 
expected to develop TSB levels that are substantially higher than those that do not have 
risk factors, and that recognizing the contribution of these risk factors to the TSB can 
avoid unnecessary laboratory investigations in an attempt to identify the cause of the 
jaundice.  We pointed out that the definitions of normal bilirubin levels found in current 
texts of the time created, in essence, a class of healthy, jaundiced babies with “non-
disease.”  It was clear from these data that, in many jaundiced infants with known risk 
factors, as long as significant pathology such as hemolytic disease was ruled out, a 
policy of watchful expectancy was justified rather than a battery of laboratory tests.  On 
the other hand an apparently normal (physiologic) TSB level in a low risk infant might 
arouse suspicion and require further investigation.  This study showed that an 
awareness of these risk factors and their potential contribution to TSB levels permitted a 
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more rational approach to the action levels used for the investigation of jaundice in the 
newborn and what was needed was a new definition of what is and is not “physiologic 
jaundice.”   
 
Length of Stay, Jaundice, and Hospital Readmission 
In a subsequent large study we reviewed the number of infants who were readmitted to 
the hospital within 14 days of discharge with a diagnosis of hyperbilirubinemia.13 Over a 
period of 6 years (1988-1994), 247 (0.8%) of 29,934 infants discharged from the 
nursery were readmitted by the age of 14 days.  127 (51%) were admitted because of 
hyperbilirubinemia and 74 (30%) with the diagnosis of “rule out sepsis.”  The factors that 
were associated with the readmission for jaundice were gestation ≤ 38 weeks, the 
identification of jaundice during the nursery stay, length of stay in the nursery of < 72 
hours, male sex and breastfeeding.  At this time, there was increasing pressure to 
discharge infants earlier from the hospital following birth and we were able to 
demonstrate that discharge at < 72 hours significantly increased the risk for readmission 
with hyperbilirubinemia.  The American Academy of Pediatrics (AAP) had previously 
recommended that infants discharged at < 48 hours should be seen by a health care 
professional within 2-3 days of discharge.  Our observations suggested that this 
recommendation should be extended to those discharged at < 72 hours after birth and 
the AAP has, subsequently, amended its recommendation consistent with these 
observations.  
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Hyperbilirubinemia and Sepsis 
Because bacterial infection is a potential cause of hyperbilirubinemia, some authors 
have suggested that newborns with significant unexplained indirect hyperbilirubinemia 
should be evaluated for sepsis.  To look at this question we reviewed the charts of 306 
newborns admitted to the pediatric ward within 21 days of birth with a diagnosis of 
indirect hyperbilirubinemia (peak serum bilirubin level 18.5 ± 2.8 mg/dL (316 ± 48 
µmol/L).14  Sepsis was not identified in any of these 306 infants (upper 95% confidence 
limit for the risk of sepsis = 1%).  90% of these infants were fully or partially breastfed.  
We concluded that the overwhelming majority of newborns who require admission to 
hospital for indirect hyperbilirubinemia are healthy, breastfed newborns and unless they 
have clinical signs suggesting sepsis, they do not need to be investigated for sepsis. 
 
PATHOGENESIS – STUDIES OF ENDOGENOUS CARBON MONOXIDE 
PRODUCTION 
Why some newborns develop hyperbilirubinemia is a question that is still being 
investigated.  Although it is clear that newborn infants produce more bilirubin than 
adults, have a limited ability to conjugate and excrete bilirubin and have an increased 
absorption of bilirubin via the enterohepatic circulation, which of these mechanisms 
predominates in individual infants is often not clear.  Currently there is intensive 
investigation into the polymorphisms of the genes controlling conjugation and bilirubin 
uptake and there is evidence that they may play a far more important role in neonatal 
hyperbilirubinemia than has previously been appreciated.  My interest in this area dates 
back to the late 1960’s when I became aware of the work of Ronald Coburn at the 
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University of Pennsylvania.  In a series of seminal studies, Coburn confirmed previous 
observations that carbon monoxide (CO) is endogenously produced in normal man and 
that approximately one mole of CO is produced per mole of heme catabolized.  As one 
mole of bilirubin is also produced per mole of heme catabolized, the measurement of 
CO production is a direct measurement of heme catabolism and therefore bilirubin 
production. 
 
Endogenous Production of Carbon Monoxidin Normal and Erythroblastostic 
Newborn Infants 
In order to measure CO production, I developed a rebreathing system for the newborn 
infant.15   In this system, the infant’s face is sealed into an airtight rebreathing mask for 
up to 3 hours, CO2 is absorbed and oxygen supplied.  Blood is sampled every 30 
minutes and analyzed for carboxyhemoglobin.  The rate of rise in carboxyhemoglobin 
corrected for a dilution factor (the increase of blood carboxyhemoglobin produced by the 
addition of a known amount of CO to the system) allows the calculation of total CO 
production.  These data were then used to calculate mean red cell life span and the rate 
of bilirubin production.  In 9 term infants (40-41 weeks gestation) studied at an average 
age of 45 hours, mean red cell life span was 88.1 ± 15.1 days and the calculated 
bilirubin production was 8.5 ± 2.3 mg/k/24 hrs.  Using the plasma bilirubin 
concentrations in these infants we were able to calculate the retention of intravascular 
bilirubin from the measured rise in serum bilirubin concentration per 24 hours and the 
plasma volume.  These calculations indicated that, on average, these infants were 
excreting 5.6 ± 2.3 mg/kg/24 hr of bilirubin.  We also studied 4 infants with 
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erythroblastosis fetalis, 3 with Rh disease and 1 with AO incompatibility.  In these 
infants the CO production rates were 3 to 11 times greater than those in the normal 
infants and their rates of bilirubin production ranged from 23 to 96 mg/kg/24 hr. 
 
Recognizing that normal newborns produce bilirubin at more than twice the adult rate 
(per kg/24 hr) suggested that the inability to conjugate bilirubin (as a result of 
inadequate glucuronosy transferase) may be less important than previously thought.  
Some 35 years later we were able to confirm this observation using a different method 
for measuring CO production (see below). 
 
We subsequently reported data from an additional 17 infants in whom carbon monoxide 
production was measured using the rebreathing system.16  When we evaluated all 26 
infants, we were unable to show a relationship between the measurements of CO 
production and either the peak TSB levels or reticulocyte counts.  We concluded that a 
single measurement of CO production was unlikely to be useful in predicting which 
infants would subsequently develop hyperbilirubinemia and we confirmed these 
observations many years later (see below).  
 
Exchange Transfusions and CO Production 
We utilized our technique for measuring endogenous CO production to elucidate the 
mechanism of the “late” post exchange transfusion bilirubin rebound.17 During an 
exchange transfusion, extravascular bilirubin equilibrates with plasma bilirubin and 
immediately after the exchange further equilibration takes place, which is complete 
 17 
within 30 minutes.  Thus there is always some degree of bilirubin rebound following an 
exchange transfusion.  In a significant percentage of infants with hemolytic disease, 
however, a further increase in bilirubin concentration occurs after the initial rebound 
necessitating one or more further exchange transfusions.  In the days when Rh disease 
was common and before the advent of phototherapy, it was not unusual to have to 
perform as many as 3 or 4 exchange transfusions on an affected infant.  Using our 
rebreathing system, we measured the endogenous production of CO in 4 infants before 
and after each exchange transfusion was performed.  As anticipated, before the first 
exchange transfusion, every infant had a significantly increased rate of CO production, 
but markedly increased CO production rates were also found after 2, or in one case 3, 
exchange transfusions had been completed.  Once CO production rates had fallen into 
the normal range, no further exchange transfusions were needed.  These data were the 
first to confirm that a continued increase in heme turnover and bilirubin production was 
primarily responsible for the late bilirubin rebound that occurs after exchange 
transfusions. 
 
End-Tidal Carbon Monoxide Measurements 
The development of a technique for measuring end-tidal carbon monoxide, corrected for 
ambient CO (ETCOc), by David Stevenson and Henk Vreman at Stanford, greatly 
simplified the ability to use measurements of CO production as an index of heme 
catabolism.  Measurement of ETCOc is completely non-invasive and requires the 
sampling of expired gas from the infant’s nostril.  The gas is drawn into an analyzer that 
measures the CO concentration with an accuracy of ± 0.3 ppm.  The measurement 
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requires about 5-10 minutes.  In a multinational study, ETCOc was measured in 1,370 
neonates in 4 countries and 9 clinical sites.18  The hypothesis was that measurement of 
ETCOc at approximately 30 hours of life would identify infants who were producing 
more bilirubin (i.e., hemolysising) and were therefore at a greater risk for the 
subsequent development of hyperbilirubinemia.  TSB levels were measured in all 
infants at age 96 hours.  Although this study showed that an increase in ETCOc had 
some predictive value in indicating which infants might subsequently develop an 
elevated TSB level, the measurement of ETCOc was not as good as the measurement 
of a predischarge TSB alone in predicting the likelihood of hyperbilirubinemia.   
 
Does Hemolysis Contribute to Early Jaundice in the Newborn? 
As an extension of my original work on the measurement of CO production, I utilized 
ETCOc measurements to examine a fundamental question in the pathogenesis of 
neonatal jaundice:  what is the contribution of increased heme turnover (hemolysis) to 
the development of hyperbilirubinemia in newborns in the first 4 days after birth.  We 
measured ETCOc in 108 jaundiced newborns and 164 control newborns in our well 
infant nursery.19  All infants were ≥ 36 weeks of gestation and well.  The jaundiced 
infants were identified with a standard nursery protocol that relied on TcB 
measurements to identify infants who required a TSB measurement.  Those infants 
whose TSB concentrations exceeded the 75th percentile for age on the Bhutani 
nomogram were classified as cases.  The control group was a convenience sample of 
infants of similar age in the well infant nursery.  Infants qualified as controls if they were 
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not jaundiced at the time of the ETCOc measurement or, if they were jaundiced, their 
TSB level did not exceed the 75th percentile. 
 
The mean ETCOc values decreased in the control group each day over the first 4 days 
but increased in the hyperbilirubinemic group, and the differences between the 
jaundiced and nonjaundiced infants were highly statistically significant on all days 
(p=0.000).  Under normal circumstances, one would expect that approximately 50% of 
ETCOc measurements would be above the mean but in our jaundiced population, 82% 
of their ETCOc values were above the mean and 26% were more than 2 standard 
deviations above the mean value for the control infants.  Thus, before hospital 
discharge, most infants at ≥ 36 weeks of gestation, with TSB levels above the 75th 
percentile are producing significantly more bilirubin than those with lower TSB levels.  
This suggests that increased heme catabolism, or hemolysis, is the primary mechanism 
responsible for hyperbilirubinemia in the first 4 days after birth.   
 
MANAGEMENT 
Management of Hyperbilirubinemia in the Breastfed Newborn 
The association between breastfeeding and hyperbilirubinemia in the newborn is now 
well established but questions remain regarding the best approach to the management 
of jaundice in the breastfed infant.  Recommended approaches include using 
phototherapy, supplementing the breastfeeding with formula, discontinuing 
breastfeeding and substituting formula, etc.  We conducted a randomized, controlled 
trial at the Hospital Materno-Infantil “R. Sarda” in Buenos Aires.20  In this study 125 full 
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term breastfed infants were evaluated each day for the presence of jaundice.  Based on 
clinical judgment, a TSB was obtained and then repeated daily until the infants were 
discharged.  Infants jaundiced at discharge were followed daily as outpatients until the 
bilirubin had reached its peak and started to decline.  If the TSB concentration reached 
or exceeded 17 mg/dL (291 µmol/L) the infants were enrolled in the study.  Study 
infants were randomly assigned to one of 4 groups: 1) continue breastfeeding 2) 
discontinue breastfeeding, substitute formula 3) discontinue breastfeeding, substitute 
formula, administer phototherapy 4) continue breastfeeding, administer phototherapy.  
The largest decline in TSB levels occurred in both of the phototherapy groups (3 and 4) 
and the differences between groups (3 and 4) were not significant.  The other outcome 
variable was how many infants developed a TSB > 20 mg/dL (342 µmol/L).  This 
occurred in only one (3%) of infants in group 3.  On the other hand, it only occurred in 
6/25 (24%) of infants in group 1, implying that if no intervention other than continuing 
breastfeeding is employed in an infant whose bilirubin level is 17 mg/dL, (291 µmol/L) 
the TSB will not reach 20 mg/dL (341 µmol/L) in 75% of these infants.  Thus, watchful 
expectancy in this situation is quite justified.   
 
Breastfeeding Frequency and Bilirubin Levels 
Although observational studies suggested that more frequent breastfeeding in the first 
few days after birth was associated with lower TSB levels, no randomized trial 
evaluating this process had been performed.  We therefore studied the effect of 
breastfeeding frequency on TSB levels in the first 3 days after birth.21  275 infants were 
randomly assigned to a frequent or demand breastfeeding schedule.  In the frequent 
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group, infants nursed on average 9 times/day and in the demand group 6.5 times/day.  
The TSB level between 48 and 80 hours (median 53 hours) was 7.4 mg/dL (127 µmul/L) 
in the frequent group and 8.0 mg/dL (137 µmul/L) in the demand group (p=.103).  
Although we could not demonstrate a significant effect on TSB levels as a result of more 
frequent nursing in this population, there was a trend toward lower levels in those fed 
more frequently.  Because of the limitations of the length of stay in hospital, it was 
necessary to measure the TSB levels on average at age 53 hours.  If we had been able 
to follow these infants for longer we might well have been able to demonstrate that 
frequent feeding was associated with lower TSB levels. 
 
TREATMENT – STUDIES ON EXCHANGE TRANSFUSION AND PHOTOTHERAPY 
 
Exchange Transfusion and Ionized Calcium 
Almost all exchange transfusions today are carried out using citrate phosphate dextrose 
(CPD) blood although, prior to its development, acid citrate dextrose (ACD) blood was 
commonly used.  Because of the binding effect of citrate on the calcium ion, it was 
recognized that the ionized calcium would decrease when an exchange transfusion was 
performed with either ACD or CPD blood and it had long been a recommended practice 
to infuse calcium gluconate at regular intervals during the exchange transfusion in order 
to counteract the known binding effect of citrate on the calcium ion.  Although widely 
practiced, there was no experimental evidence to indicate that the use of calcium 
gluconate had any beneficial effect on calcium ion homeostasis during exchange 
transfusion.  We took advantage of the development of a calcium iron-selective 
electrode to study the effect of exchange transfusion and of added calcium gluconate on 
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the serum ionized calcium concentration.22  We studied 18 newborn infants during 27 
exchange transfusions.  We measured the total and ionized calcium concentration 
immediately before the exchange and after every 100 ml exchanged, and 2 hours and 4 
hours after the exchange.  When heparinized blood was used there were negligible 
changes in the ionized calcium concentration, whereas with ACD blood there was a 
significant fall in the ionized calcium.  Nevertheless, this fall was not prevented by the 
infusion of calcium gluconate.  Although the infusion of calcium gluconate temporarily 
increased the ionized calcium level, it immediately decreased as the exchange 
transfusion continued.  It had also been a practice to infuse additional calcium if infants 
were noted to be irritable or crying or jittery during the exchange transfusion.  We 
recorded the infant’s clinical state as quiet or sleeping or crying or irritable during the 
exchange and correlated these findings with the serum ionized calcium concentrations.  
There was no association between the levels of ionized calcium and the clinical signs 
and symptoms indicating that other factors must be responsible for these changes in 
infant’s behavior during exchange transfusion. 
 
PHOTOTHERAPY 
Phototoxicity to the Retina 
With the introduction of phototherapy, it was generally accepted that it was important to 
protect the infant’s eyes from direct exposure to the phototherapy lights because of the 
potential for damage to the newborn’s retina.  Although the toxic effect of light on the 
retina had been demonstrated in rats, piglets and pigeons, no such studies had been 
done in the newborn subhuman primate.  In addition, in almost all of the published 
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studies, the animals’ eyes were kept open with sutures, and mydriatic drops were used 
to provide pupillary dilatation.  In our study we used newborn stump-tail monkeys, 
weighing 450-500g and exposed them to cool white fluorescent light from a standard 
phototherapy lamp for periods of 12hr, 24hr, 3 days and 7 days.23  These monkeys were 
kept in standard infant incubators and a restraining device was used inside the 
incubator to maintain the monkey in a supine position facing the light source.  On the 
other hand, no mydriatic drops were placed in the eyes and the monkeys could close 
their eyes as desired.  The left eye was used as the study eye and the right eye was the 
control.  The right eye was sutured closed and covered with a patch of black velour 
material.  The exposed eyes showed progressive damage to the retina even after only 
12 hours of exposure.  We, therefore, concluded that there was a sound basis for the 
recommended practice of patching the eyes of infants undergoing phototherapy.   
 
Fiberoptic Phototherapy 
Fiberoptic phototherapy systems are convenient in that they can provide phototherapy 
without the need for eye patching and they allow a mother to hold her newborn while the 
infant receives phototherapy.  On the other hand, because of the physical properties of 
a light source that is remote from the blanket or pad through which the phototherapy is 
delivered, the size of the phototherapy pads has been kept small in order to maintain a 
higher irradiance.  Making the pads larger would decrease the irradiance although it 
would increase the surface area of the baby exposed to phototherapy.  We conducted a 
randomized controlled trial to compare fiberoptic phototherapy with conventional 
phototherapy in healthy jaundiced newborns with birth weights > 2500 g.24  Both 
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methods of phototherapy were effective in lowering the TSB but the mean TSB was 
lower after 18 hours of therapy in the conventional phototherapy group.  On the other 
hand, the conventional phototherapy lights produced an average irradiance of 9.2 
µW/cm2/nm versus 8.2 µW/cm2/nm in the fiberoptic group.  In addition, the area of skin 
exposed to standard phototherapy lights is substantially greater than the area that 
receives phototherapy when fiberoptic pads or blankets are used and the exposure of a 
larger surface area of the infant to phototherapy produces a more significant decline in 
the TSB. 
 
Double Phototherapy 
The availability of fiberoptic phototherapy makes it easy to administer conventional 
phototherapy from above while the infant lies on a fiberoptic phototherapy blanket.  In 
this study, newborns with birth weights <2500 g were randomly assigned to receive 
either single or double phototherapy.25  After 18 hours of therapy, the serum bilirubin 
concentration declined by 31 ± 11% in the double phototherapy group and 16 ± 15% in 
the single phototherapy group.  The irradiance delivered in the two groups was similar 
but the newborns receiving double phototherapy had a larger surface area exposed, so 
that the total dose of phototherapy was increased.  These data demonstrated 
conclusively that increasing the surface area of the infant exposed to phototherapy 
significantly improves its efficacy. 
 
Light Emitting Diodes 
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The most recent addition to the armamentarium of phototherapy is the light-emitting 
diode (LED).  LED lights are power-efficient, durable light sources that provide high 
intensity light in the blue portion of the visible spectrum.  LED lights do not emit 
significant infrared or ultraviolet radiation and produce minimum radiant heat.  The small 
size, high luminous intensity and narrow wavelength band light of LED phototherapy 
makes this a useful method for delivering intensive phototherapy to newborn infants.   
In a randomized, controlled trial, we compared the efficacy of LED phototherapy with 
special blue fluorescent (BB) tube phototherapy in the treatment of neonatal 
hyperbilirubinemia.26  In this study we randomly assigned 66 infants ≥ 35 weeks of 
gestation to receive phototherapy using a LED device or BB.  In addition to 
phototherapy from above, all infants also received phototherapy from below using 4 BB 
tubes or a fiberoptic pad.  After 15 ± 5 hours of phototherapy the rate of decline in the 
total serum bilirubin (TSB) was 0.35 ± 0.25 mg/dL/h (6.0 ± 4.3 µmol/L/h) in the LED 
group versus 0.27 ± 0.25 mg/dL/h (4.6 ± 4.3 µmol/L/h) in the BB group (p=0.20).  We 
concluded that LED phototherapy is as effective as BB phototherapy in lowering serum 
bilirubin levels in term and late preterm newborns. 
 
“Homeopathic” vs Intensive Phototherapy 
In 1996 I published a commentary entitled “Why use homeopathic doses of 
phototherapy.”27  Although this publication took the form of a brief review, it did contain 
original data regarding the effect of the light source and distance from the light source 
on the irradiance delivered to the infant.  In addition to discussing the efficacy of 
phototherapy and how it is affected by the light spectrum, the irradiance, the surface 
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area, and the spectral power delivered to the newborn, I noted that, although in use in 
the United States for more than a quarter of a century, the way in which phototherapy 
was delivered was frequently not effective.  Phototherapy was used initially to prevent 
the TSB levels from reaching exchange transfusion levels in preterm infants.  The 
subsequent move toward early discharge of infants from the nursery led to more infants 
being readmitted with significant elevations of serum bilirubin, some as high as 25 
mg/dL (428 µmol/L).  In these infants it was necessary to reduce the serum bilirubin 
level as rapidly as possible and for this type of infant intensive phototherapy was 
necessary.  In addition to the general discussion of phototherapy presented in this 
paper, we measured the effect of the type of light source used, as well as the distance 
of the light source from the infant on the spectral irradiance.  We were able to show that 
conventional phototherapy lights (daylight or regular blue lights) when placed 30 cm 
from the infant delivered an irradiance of about 8-10 µW/cm2/nm.  At the same distance 
from the infant, special blue fluorescent tubes delivered 30 µW/cm2/nm and, when 
placed 10 cm from the infant, the special blue tubes delivered 60 µW/cm2/nm whereas 
the conventional phototherapy lights delivered about 12-15 µW/cm2/nm.  We were thus 
able to demonstrate the importance of understanding the effect on irradiance of the type 
of light used and the distance between the light source and the infant.   
 
The Effect of Phototherapy on Exchange Transfusion 
In this paper I analyzed the impact of the introduction of phototherapy on the number of 
exchange transfusions performed.28  I was able to show that in the 1950’s and early 
60’s, prior to the introduction of phototherapy, the rate of exchange transfusions for all 
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infants was about 43/10,000 live births.  Phototherapy was introduced in the late 1960’s 
and, by the 1980’s and 90’s, the rate of exchange transfusions had fallen to 1.6/10,000 
live births.  During this time period, of course, the use of anti-D gamma globulin had 
been introduced to prevent Rh hemolytic disease and this undoubtly had an impact on 
the number of exchange transfusions needed.  Nevertheless, the use of intensive 
phototherapy has had a dramatic effect on decreasing the need for exchange 
transfusions in both ABO and Rh hemolytic disease.  When one looks at infants with 
birthweights less than 1500 g the impact has been even more dramatic.  In the absence 
of phototherapy, 36% of infants with birth weights <1500 g received at least one 
exchange transfusion.  Between January 1988 and October 2007, not a single 
exchange transfusion has been performed at the William Beaumont Hospital on 2425 
infants who weighted < 1500 g at birth. 
 
Bilirubin Rebound Following Phototherapy 
The use of intensive phototherapy has raised additional questions.  It was well 
documented that, following the discontinuation of conventional phototherapy, some 
rebound in the TSB level usually occurred, but this question had not been studied in 
infants receiving intensive phototherapy. 
 
We studied two groups of infants - those who received intensive phototherapy in our 
well baby nursery during their birth hospitalization and a second group who had been 
discharged from the nursery and were readmitted for phototherapy.29  In the infants who 
received phototherapy during their birth hospitalization, 8.2% had a rebound sufficient to 
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require additional phototherapy whereas only 1 (0.7%) of 144 infants who first received 
phototherapy on readmission required additional phototherapy.  We concluded that it 
was not necessary to keep infants in the hospital to check for rebound although it was 
clear that those who required phototherapy during their birth hospitalization were more 
likely to have a significant rebound than those admitted later.  The incidence of ABO 
blood group incompatibility with a positive direct Coombs’ test in the infants receiving 
phototherapy before discharge was 22% compared with only 3.5% in those infants who 
were readmitted for phototherapy.  Thus, the infants receiving phototherapy before 
discharge from the hospital are much more likely to have some degree of hemolysis and 
are therefore more likely to have a rebound in serum bilirubin.   
 
Does Intensive Phototherapy Produce Hemolysis? 
The other question that has arisen regarding intensive phototherapy is - could it produce 
hemolysis?  There is some in vitro evidence that phototherapy can increase the 
erythrocyte osmotic fragility and produce lipid peroxidation of the red cell membrane 
leading to hemolysis. 
 
We measured end tidal CO concentration corrected for ambient CO (ETCOc) before, 
during and after phototherapy in infants receiving intensive phototherapy.30  In a study 
of 27 infants ≥ 35 weeks of gestation, there was a steady decrease in the mean ETCOc 
over the course of phototherapy and we were able to conclude that there was no 
evidence that intensive phototherapy produced hemolysis in these infants. 
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BILIRUBIN ENCEPHALOPATHY 
 
Does Hyperbilirubinemia Damage the Brain of Healthy Full-Term Infants? 
A question that has long been asked is whether or not hyperbilirubinemia is damaging 
to the brain of healthy full-term infants.  While it is certain that if TSB levels are high 
enough, they can cause kernicterus (see below), it was a standard recommendation in 
textbooks that whenever the TSB level reached 20 mg/dL (342 µmol/L) an exchange 
transfusion should be performed, irrespective of the cause of the hyperbilirubinemia.  In 
this paper, Thomas B. Newman and I reviewed the world’s literature on this subject in 
considerable detail looking at all of the published studies dealing with the effects of 
hyperbilirubinemia on cognition, neurologic abnormality and on hearing.31 This analysis 
included a discussion of the effects of confounding and effect modification, whether or 
not the correct “risk factor” was being measured, and finally the importance of clinical 
versus statistical significance.  We were able to conclude that no evidence exists to 
support the view that bilirubin levels of 20 mg/dL (342 µmol/L) are hazardous to healthy 
term infants and this conclusion has been confirmed in recent studies. 
 
New Guidelines for Management 
A follow up on this review was a more focused discussion of the management of 
hyperbilirubinemia in which we proposed new guidelines for the treatment of these 
infants.32 
 
 30 
An Animal Model of Bilirubin Encephalopathy 
In most animal species, hyperbilirubinemia alone fails to produce kernicterus but when 
accompanied by additional insults to the nervous system, such as asphyxia, kernicterus 
can occur.  To further elucidate this process, we examined the effect of 
hyperbilirubinemia on the brain stem auditory evoked responses (BAER) in the 
paralyzed, ventilated adult rat.33  The infusion of bilirubin alone failed to produce 
changes from control values in the BAER.  In asphyxiated animals, however, 
progressive deterioration in the BAER was seen in 58% of the surviving asphyxiated 
animals who received bilirubin.  These changes were not seen in any of the asphyxiated 
animals who did not receive bilirubin.  The secondary deterioration of the BAER 
involved all 4 major waves, suggesting that the toxicity affected either the 
cochlea/auditory nerve (represented by wave I) or the brainstem auditory pathway, 
reflected by subsequent waves.  These data confirmed that monitoring the BAER could 
be useful as a non-invasive means of identifying bilirubin toxicity in the newborn.   
 
Kernicterus in Healthy Term Newborns 
If TSB levels are sufficiently elevated, kernicterus will occur and we documented this in 
a report of 6 infants born between 1979-1991 whose peak recorded TSB levels 
occurred 4-10 days after birth and ranged from 39.9-49.7 mg/dL (667-850 µmol/L).34 
None of these infants had laboratory findings consistent with hemolysis and no cause 
was found for the hyperbilirubinemia other than its association with breastfeeding.  We 
concluded that although rare, classic kernicterus can occur in apparently healthy, full-
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term breastfed newborns who do not have hemolytic disease or any other discernable 
cause for their jaundice. 
 
Kernicterus is Still Occurring 
I subsequently authored a commentary to bring the attention of the paediatric 
community to the issue of kernicterus which is still occurring today.35  This commentary 
was followed by the Clinical Practice Guideline of the American Academy of Pediatrics 
on the management of hyperbilirubinemia in the newborn infant 35 or weeks of 
gestation.36  I was the principal author of this guideline which is widely used throughout 
the world.  As background to this guideline, it was necessary to produce an evidence-
based review of the issues that were being considered by the academy’s subcommittee.  
I participated in this technical report and contributed the information on the risks of 
exchange transfusion.37 
 
Bilirubin as an Antioxidant 
Although bilirubin is known to be toxic to the central nervous system, it is also one of the 
most powerful antioxidants that we possess and, at the tissue level, exerts a more 
powerful antioxidant effect than does alfa-tocopherol (vitamin E).  It is known that 
oxidative injury contributes to the development of retinopathy of prematurity (ROP) and, 
because of its antioxidant properties, we wondered whether or not bilirubin might have a 
role in preventing ROP in the extremely low birth weight infant.  We therefore evaluated 
the relationship of ROP to bilirubin levels in 157 infants born at 23 to 26 weeks 
estimated gestational age.38  For each infant we calculated the average of all bilirubin 
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levels obtained on each day for the first 15 days of post natal life.  The mean bilirubin 
level over the first 15 days in infants with mild ROP was 5.0 ± 0.8 mg/dL (428 ± 14 
µmol/L) and 4.7 ± 0.7 mg/dL (80 ± 12 µmol/L) in those with severe ROP (not significant).  
When the groups were further subdivided into the individual stages of ROP, no 
significant differences in mean TSB levels were found.  However, when the groups were 
arbitrally divided by average bilirubin levels, we did find that a significantly higher 
proportion of infants with severe ROP had average bilirubin levels of < 5 mg/dL (85 
µmol/L).  This result could have been a function of the fact that those infants with severe 
ROP were smaller and less mature and would therefore have received earlier and more 
aggressive phototherapy. 
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